The/B-ORG Food/I-ORG and/I-ORG Drug/I-ORG Administration/I-ORG said/O American/B-ORG Home/I-ORG Products/I-ORG Corp./I-ORG agreed/O to/O recall/O certain/O generic/O drugs/O that/O were/O produced/O by/O its/O Quantum/B-ORG Pharmics/I-ORG unit/O in/O Amityville/B-GPE ,/O N.Y/B-GPE ./O
Quantum/B-ORG stopped/O shipping/O the/O drugs/O last/O month/O ,/O following/O a/O federal/O investigation/O regarding/O information/O the/O company/O supplied/O to/O obtain/O three/O drug/O approvals/O ./O
The/O FDA/B-ORG requested/O the/O recall/O of/O Quantum/B-ORG 's/O mioxidil/O tablets/O ,/O chlorazepate/O dipotassium/O tablets/O and/O meclofenamate/O sodium/O capsules/O because/O ,/O it/O said/O ,/O the/O size/O of/O the/O production/O runs/O submitted/O for/O testing/O to/O gain/O FDA/B-ORG approval/O was/O in/O each/O case/O misrepresented/O as/O much/O larger/O than/O it/O actually/O was/O ./O
American/B-ORG Home/I-ORG Products/I-ORG ,/O based/O in/O New/B-GPE York/I-GPE ,/O agreed/O to/O recall/O four/O other/O products/O ,/O trazadone/O ,/O doxepin/O ,/O diazepam/O and/O lorazapam/O ,/O because/O of/O concerns/O about/O data/O submitted/O in/O their/O original/O approval/O applications/O before/O the/O FDA/B-ORG ./O
No/O safety/O problems/O with/O the/O products/O are/O known/O ,/O the/O FDA/B-ORG said/O ./O
An/O FDA/B-ORG spokesperson/O said/O the/O drugs/O are/O still/O available/O under/O other/O brand/O names/O ./O
Last/O month/O ,/O American/B-ORG Home/I-ORG Products/I-ORG said/O it/O was/O suspending/O production/O and/O distribution/O of/O all/O 21/O of/O Quantum/B-ORG 's/O generic/O drug/O products/O pending/O the/O completion/O of/O an/O exhaustive/O internal/O audit/O ./O
It/O also/O temporarily/O closed/O Quantum/B-ORG ,/O because/O of/O the/O internal/O investigation/O ,/O as/O well/O as/O the/O FDA/B-ORG 's/O ongoing/O inquiry/O ./O
In/O New/B-ORG York/I-ORG Stock/I-ORG Exchange/I-ORG composite/O trading/O ,/O American/B-ORG Home/I-ORG Products/I-ORG rose/O 75/O cents/O to/O $/O 105/O on/O Friday/O ./O
